Neurocrine Biosciences (FRA:NB3) Institutional Ownership: 68.24% (As of Jul. 28, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:NB3 Neurocrine Biosciences Inc FRA:NB3
94 GF Score
Price €156.80
GF Value €170.80
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Neurocrine Biosciences Institutional Ownership?

Neurocrine Biosciences FRA:NB3 +3.64% 94 Institutional Ownership is 68.24% as of Jul. 28, 2026. GuruFocus rates FRA:NB3 with a GF Score™ of 94/100 and a GF Value™ of €170.80 (Fairly Valued). The stock has 6 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Neurocrine Biosciences's institutional ownership is 68.24%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Neurocrine Biosciences's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Neurocrine Biosciences's Float Percentage Of Total Shares Outstanding is 76.76%.

Neurocrine Biosciences Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Neurocrine Biosciences's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurocrine Biosciences Institutional Ownership Chart

Neurocrine Biosciences Historical Data

The historical data trend for Neurocrine Biosciences can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 70.98 70.45 70.18 66.93 66.10 64.75 65.91 66.22 67.35 68.24
FRA:NB3
94GF Score
Neurocrine Biosciences Inc FRA:NB3
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neurocrine Biosciences Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 68.24% mean?
Neurocrine Biosciences (FRA:NB3) has a Institutional Ownership of 68.24% as of Jul. 28, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Neurocrine Biosciences and its competitors.
Is Neurocrine Biosciences' Institutional Ownership too high?
Neurocrine Biosciences' current Institutional Ownership is 68.24%. Overall, Neurocrine Biosciences has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Neurocrine Biosciences' Institutional Ownership compare to VTRS and UTHR?
Neurocrine Biosciences' Institutional Ownership of 68.24% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Drug Manufacturers company?
A good Institutional Ownership depends on the Drug Manufacturers industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Neurocrine Biosciences and its competitors. Neurocrine Biosciences's current Institutional Ownership is 68.24%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurocrine Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Neurocrine Biosciences (FRA:NB3) is currently considered Fairly Valued. The stock's GF Value™ is €170.80, compared to a current price of €156.80 — trading 8.2% below its estimated fair value. The current Institutional Ownership is 68.24%. Neurocrine Biosciences' overall GF Score™ is 94/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Neurocrine Biosciences (FRA:NB3), the current Institutional Ownership is 68.24% as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neurocrine Biosciences (FRA:NB3) Overvalued in 2026?

Based on GuruFocus' analysis, Neurocrine Biosciences stock appears to be undervalued. The current stock price of €156.80 is trading 8.2% below its estimated GF Value™ of €170.80. GuruFocus considers Neurocrine Biosciences to be Fairly Valued.

Key valuation signals for FRA:NB3:

  • Institutional Ownership: 68.24%
  • GF Value™: €170.80 vs. price of €156.80 (8.2% below fair value)
  • GF Score™: 94/100 with 6 warning signs

No single metric tells the full story. See the FRA:NB3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Neurocrine Biosciences Business Description

Address 6027 Edgewood Bend Court, San Diego, CA, USA, 92130
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
94GF Score

Get the complete analysis for FRA:NB3

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€156.80
Price
€170.80
GF Value